Novo Pulls Wegovy Heart Failure Application, Will Resubmit To Get ‘Hard Endpoints’ In Label

 
• By Jessica Merrill and Kevin Grogan
  
The FDA had some disappointing news for Novo Nordisk. • Source: Shutterstock

More from Clinical Trials

More from R&D